CGT Manufacturing Challenges and Opportunities

The State of CDMO Funding: 2025 in Review (Part Two)

The State of CDMO Funding: 2025 in Review (Part One)

Corporate compliance involves more than just cGMP and quality

Charting Pharma Manufacturing Trends: Part Two

Charting Pharma Manufacturing Trends: Part One

Editor’s (re)View: It matters if Big Pharma is fudging its US investment numbers

Can CDMOs keep up with the increasing demand for GLP-1 medications?

FDA’s program to speed up US manufacturing buildouts is short on detail

New Jersey remains hot life sciences hub despite macroeconomic, funding headwinds

Critical Timing: Hikma’s Billion-Dollar U.S. Investment

Editor’s (re)View: Is the biopharma industry’s glass half empty or half full?

Life sciences manufacturers overwhelmingly embrace smart tech: global survey

Flow state: The evolving shape of continuous manufacturing

[Solutions Spotlight] Hydrogenation: Bridging the gap between nitration and phosgenation

Editor’s (re)View: BMS, Merck, Roche see manufacturing flexibility as key to dealing with tariffs

Thermo Fisher opens cell therapy center, FDA cites Aurobindo site, Trump probes pharma imports ahead of tariffs [The good, the bad, the ugly]

Novartis to invest $23B in US sites, US urged to invest $15B in biotech counter to China, Trump warns of major pharma tariffs [The good, the bad, the ugly]

Cellares, Cabaletta validate automated CAR T production, FDA warns Aspen over sterility issues, rejects Hengrui, Elevar cancer combo again [The good, the bad, the ugly]

Axplora expands ADC capacity, Merck KGaA CDMO business slump, FDA issues a warning letter to Granules India [The good, the bad, the ugly]